

PCT  
JC10 Rec'd PCT/PTO 28 OCT 2005  
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of

Docket No: Q86049

Nicoletta BIANCHI, *et al.*

Appln. No.: 10/522,737

Group Art Unit: Not yet assigned

Confirmation No.: 8521

Examiner: Not yet assigned

Filed: January 28, 2005

For: USE OF ANGELICIN AND OF ITS STRUCTURAL ANALOGUES FOR THE  
TREATMENT OF THALASSEMIA

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

Each of the listed references is cited in the specification of the above-identified application.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

  
Susan J. Mack  
Registration No. 30,951

Date: October 28, 2005

Substitute for Form 1449 A &amp; B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number 0/522,737  
 Confirmation Number 8521  
 Filing Date January 28, 2005  
 First Named Inventor Nicoletta BIANCHI  
 Art Unit Not yet assigned  
 Examiner Name Not yet assigned  
 Attorney Docket Number Q86049

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
	/	E.A. RACHMILEWITZ, <i>et al.</i> , "Novel Treatment Options in the Severe $\beta$ -Globin Disorders," <i>British Journal of Haematology</i> , 1995, Vol. 91, pages 263-268	
	/	J. ROCLETTE, <i>et al.</i> , "Fetal Hemoglobin Levels in Adults," <i>Blood Reviews</i> , 1994, Vol. 8, pages 213-224	
	/	NICOLETTA BIANCHI, <i>et al.</i> , "Accumulation of $\gamma$ -globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallismustine," <i>British Journal of Haematology</i> , 2001, Vol. 113, pages 951-961	
	/	GEORGE J. DOVER, <i>et al.</i> , "Increased Fetal Hemoglobin in Patients Receiving Sodium 4-phenylbutyrate," <i>The New England Journal of Medicine</i> , Vol. 327, No. 8, pages 569-570, August 20, 1992	
	/	TOHRU IKUTA, <i>et al.</i> , "Cellular and Molecular Effects of a Pulse Butyrate Regimen and New Inducers of Globin Gene Expression and Hematopoiesis," <i>Annals New York Academy of Sciences</i> , pages 87-99, Vol. 850, 1998	
	/	LING DONG KONG, <i>et al.</i> , "Inhibition of Rat Brain Monoamine Oxidase Activities by Psoralen and Isopsoralen: Implications for the Treatment of Affective Disorders," <i>Pharmacology &amp; Toxicology</i> , 2001, Vol. 88, pages 75-80	
	/	LUIA MOSTI, <i>et al.</i> , "Synthesis of angelicin heteranalogues: preliminary photobiological and pharmacological studies," <i>Il Farmaco</i> , Vol. 53, 1998, pages 602-610	
	/	SOROUGH SARDARI, <i>et al.</i> , "Synthesis and Antifungal Activity of Coumarins and Angular Furanocoumarins," <i>Bioorganic &amp; Medicinal Chemistry</i> , Vol. 7, 1999, pages 1933-1940	
	/	ANDREAS E. JAKOBS, <i>et al.</i> , "A Convenient Synthesis of Thiopyrano [2,3- <i>e</i> ]benzofuran: A New Sulfur Analogue of Angelicin," <i>J. Org. Chem.</i> , 1996, Vol. 61, pages 4842-4844	
	/	MARZIA IESTER, <i>et al.</i> , "Synthesis and Photobiological Properties of 3-acylangelicins, 3-alkoxycarbonylangelicins and Related Derivatives," <i>Il Farmaco</i> , Vol. 50, No. 10, pages 669-678, 1995	
	/	EMILE BISAGNI, <i>et al.</i> , "Synthesis of psoralens and analogues," <i>J. Photochem. Photobiol. B: Biol.</i> , Vol. 14, 1992, pages 23-46	
	/	FRANCESCO DALL'ACQUA, <i>et al.</i> , "4'-Methylangelicins: New Potential Agents for the Photochemotherapy of Psoriasis," <i>J. Med. Chem.</i> , 1983, Vol. 26, pages 870-876	
	/	FRANCESCO DALL'ACQUA, <i>et al.</i> , "Methylangelicins: New Potential Agents for the Photochemotherapy of Psoriasis. Structure-Activity Study on the Dark and Photochemical Interactions with DNA," <i>J. Med. Chem.</i> , 1981, Vol. 24, pages 806-811	
	/	MARIA TERESA CONCONI, <i>et al.</i> , "Antiproliferative Activity and Phototoxicity of some Methyl Derivatives of 5-Methoxypsoralen and 5-Methoxyangelicin," <i>Pharmacology &amp; Toxicology</i> , 1998, Vol. 82, pages 193-198	
	/	C. MARZANO, <i>et al.</i> , "DNA Damage and Cytotoxicity Induced in Mammalian Cells by a Tetramethylfuroquinolinone Derivative," <i>Environmental and Molecular Mutagenesis</i> , Vol. 29, pages 256-264, 1997	
	/	FRANCO BORDIN, <i>et al.</i> , "Angellicins, Angular Analogs of Psoralens: Chemistry, Photochemical, Photobiological and Phototherapeutic Properties," <i>Pharmac. Ther.</i> , Vol. 52, pages 331-363, 1991	
	/	C. NADINE BACKHOUSE, <i>et al.</i> , "Active constituents isolated from <i>Psoralea glandulosa</i> L. with anti-inflammatory and antipyretic activities," <i>Journal of Ethnopharmacology</i> , Vol. 78, 2001, pages 27-31	
	/	NICOLETTA BIANCHI, <i>et al.</i> , "Induction of Erythroid Differentiation of Human K562 Cells by Cisplatin Analogs," <i>Biochemical Pharmacology</i> , Vol. 60, pages 31-40, 2000	
	/	NICOLETTA BIANCHI, <i>et al.</i> , "The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells," <i>British Journal of Haematology</i> , 1999, Vol. 104, pages 258-265	
	/	E. FIBACH, "Techniques for Studying Stimulation of Fetal Hemoglobin Production in Human Erythroid Cultures," <i>Hemoglobin</i> , Vol. 22, Nos. 5&6, pages 445-458, 1998	
	/	EITAN FIBACH, <i>et al.</i> , "Hydroxyurea Increases Fetal Hemoglobin in Cultured Erythroid Cells Derived From Normal Individuals and Patients With Sickle Cell Anemia or $\beta$ -Thalassemia," <i>Blood</i> , Vol. 81, No. 6, pages 1630-1635, March 15, 1993	
	/	CHRISTIAN A. HEID, <i>et al.</i> , "Real Time Quantitative PCR," <i>Genome Research</i> , Vol. 6, pages 986-994, 1996	
	/	URSULA E.M. GIBSON, <i>et al.</i> , "A Novel Method for Real Time Quantitative RT-PCR," <i>Genome Research</i> , Vol. 6, pages 995-1001, 1996	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.